Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation

Eilard, Malin Sternby; Holmberg, Erik; Naredi, Peter; Söderdahl, Gunnar; Rizell, Magnus

doi:10.1080/00365521.2018.1488180

Cited by 5 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some novel indicators have been investigated for integration with AFP, such as 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) 131,132 and plasma metabolomics profiling 133 . In addition, several criteria established and validated previously were combined with AFP for the purpose of minimizing the risk of post-LT tumor recurrence 134,135 . Grąt et al cited University of California, San Francisco (UCSF) criteria, Up-to-7 criteria and AFP levels <100 ng/ml to build a score 134 .…”

Section: Afp With Other Factorsmentioning

confidence: 99%

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

Hu¹,

Chen²,

Wei³

et al. 2022

Int. J. Biol. Sci.

102

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has been acknowledged as a leading cause of death among cirrhosis patients. Difficulties in early diagnosis and heterogeneity are obstacles to effective treatment, especially for advanced HCC. Liver transplantation (LT) is considered the best therapy for HCC. Although many biomarkers are being proposed, alpha-fetoprotein (AFP), which was identified over 60 years ago, remains the most utilized. Recently, much hope has been placed in the immunogenicity of AFP to develop novel therapies, such as AFP vaccines and AFP-specific adoptive T-cell transfer (ACT). This review summarizes the performance of AFP as a biomarker for HCC diagnosis and prognosis, as well as its correlation with molecular classes. In addition, the role of AFP in LT is also described. Finally, we highlight the mechanism and application prospects of two immune therapies (AFP vaccine and ACT) for HCC. In general, our review points out the prevalence of AFP in HCC, accompanied by some controversies and novel directions for future research.

show abstract

Section: Afp With Other Factorsmentioning

confidence: 99%

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

Hu¹,

Chen²,

Wei³

et al. 2022

Int. J. Biol. Sci.

102

View full text Add to dashboard Cite

show abstract

“…15,36,37 In this Swedish National cohort study, the effect of selection for transplantation, resection or ablation respectively, was demonstrated by typical differences in demographic factors and 5yOS rates in the total treatment cohorts (Supplement 1). AFP was an important risk factor in the clinically selected transplantation cohort, 38,39 but not significant in the ablation group, including more patients with other strong risk factors. ASA 3-4 was a risk factor in the resection group, while age and multiple tumours were significant in the ablation group.…”

Section: Discussionmentioning

confidence: 80%

Survival and prognostic factors after transplantation, resection and ablation in a national cohort of early hepatocellular carcinoma

Eilard

Naredi

Helmersson

et al. 2021

HPB

Self Cite

View full text Add to dashboard Cite

Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background Patients with hepatocellular carcinoma (HCC) are selected for transplantation if they have a low tumour burden and low risk of recurrence. The morphometric Milan criteria have been the cornerstone for patient selection, but dynamic morphological and biological tumour characteristics surfaced as an encouraging tool to refine the selection of patients with HCC and to support the expansion of the Milan criteria. The outcomes of the most prevalent models that select patients with HCC for liver transplantation were analysed in this study, which aimed to identify the selection model that offered the best recurrence-free and overall survival after transplantation. Methods Studies that compared Milan, University of California San Francisco (UCSF), up-to-seven (UPTS), alpha-fetoprotein (AFP), and MetroTicket 2.0 (MT2) models were included. One-year, 3-year, and 5-year recurrence-free and overall survival rates of patients selected for transplantation using different models were analysed. Results A total of 60 850 adult patients with HCC selected for liver transplantation using Milan, UCSF, UPTS, AFP, or MT2 criteria were included. Patients selected for transplantation using the MT2 model had the highest 1-, 3-, and 5-year recurrence-free survival. In addition, patients selected for transplantation using MT2 criteria had the best 1- and 3-year overall survival, whereas patients selected for transplantation using the Milan criteria had the best 5-year overall survival rates. Conclusion The MT2 model offered the best post-transplant outcomes in patients with HCC, highlighting the importance of considering tumour morphology and biology when selecting patients with HCC for liver transplantation.

show abstract

Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation

Abstract: AFP combined with traditional selection criteria ameliorates the selection accuracy for liver transplantation in HCC.

Cited by 5 publications

References 36 publications

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

Survival and prognostic factors after transplantation, resection and ablation in a national cohort of early hepatocellular carcinoma

Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis

Contact Info

Product

Resources

About